Physician profile
Chace Franks
NPI 1215392469
$2,394.86
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $1,013 · 2023: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.91 | 2021-2023 | |
| Novo Nordisk INC | $470.44 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $366.21 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $234.75 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $160.73 | 2021-2023 | |
| Amgen INC. | $76.95 | 2021-2023 | Repatha, Otezla |
| Pfizer INC. | $69.43 | 2021-2023 | |
| Glaxosmithkline, LLC. | $63.41 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.50 | 2021 | |
| Amarin Pharma, INC. | $56.69 | 2021 | |
| Lilly USA, LLC | $52.79 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $43.10 | 2022 | |
| Esperion Therapeutics, INC. | $38.71 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $31.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.27 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2023 | Gattex |
| Exact Sciences Corporation | $16.22 | 2023 | Cologuard Collection Kit |
| Metacel Pharmaceuticals LLC | $12.69 | 2022 | |
| Astellas Pharma US INC | $12.23 | 2021 | |
| Sumitomo Pharma America, INC. | $10.20 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chace Franks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.